IFNA2 and melanoma: The A375 human melanoma cell line was then treated for 48 hours with IFN-α (104 units/mL), ixazomib (15-65 nM), or both agents combined and evaluated by immunoblot analysis for cleaved PARP, caspase-3 and caspase-7 (Figure 8B).